Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

Disclosure This research was sponsored by Teva Branded Pharmaceutical Products R&D, Inc, Frazer, PA, USA and conducted in collaboration with Evidera, Bethesda, MD, USA. CGS is an employee of Teva Branded Pharmaceutical Products R&D, Inc. At the time this study was conducted, JAS was an employee of Teva Branded Pharmaceutical Products R&D, Inc. TK, DG, and MM are employees of Evidera, which received research funding to develop the model and conduct the analysis for this study. Funding for editorial support was provided by Teva Branded Pharmaceutical Products R&D, Inc, to The Curry Rockefeller Group, LLC, Tarrytown, NY, USA. Publication of the study results was not contingent on the sponsor’s approval or censorship of the manuscript.